By Kathryn Calkins
Staff Writer

Cephalon Inc.'s Myotrophin insulin-like growth factor-1 will face its third FDA advisory panel on April 9, and a few things have changed since the company's appearances in 1996 and 1997. The FDA has additional data in hand; the composition of the panel has changed; and newly implemented fast-track regulations resulting from FDA reform provide a potentially face-saving way out of the agency's desire for more data and the company's refusal to run another study prior to approval.